Literature DB >> 26829988

PcpA Promotes Higher Levels of Infection and Modulates Recruitment of Myeloid-Derived Suppressor Cells during Pneumococcal Pneumonia.

Melissa M Walker1, Lea Novak2, Rebecca Widener3, James Aaron Grubbs4, Janice King1, Joanetha Y Hale1, Martina M Ochs5, Lisa E Myers5, David E Briles6, Jessy Deshane7.   

Abstract

We used two different <span class="Disease">infection models to investigate the kinetics of the <span class="Chemical">PcpA-dependent pneumococcal disease in mice. In a bacteremic pneumonia model, we observed a PcpA-dependent increase in bacterial burden in the lungs, blood, liver, bronchoalveolar lavage, and spleens of mice at 24 h postinfection. This PcpA-dependent effect on bacterial burden appeared earlier (within 12 h) in the focal pneumonia model, which lacks bacteremia or sepsis. Histological changes show that the ability of pneumococci to make PcpA was associated with unresolved inflammation in both models of infection. Using our bacteremic pneumonia model we further investigated the effects of PcpA on recruitment of innate immune regulatory cells. The presence of PcpA was associated with increased IL-6 levels, suppressed production of TRAIL, and reduced infiltration of polymorphonuclear cells. The ability of pneumococci to make PcpA negatively modulated both the infiltration and apoptosis of macrophages and the recruitment of myeloid-derived suppressor-like cells. The latter have been shown to facilitate the clearance and control of bacterial pneumonia. Taken together, the ability to make PcpA was strongly associated with increased bacterial burden, inflammation, and negative regulation of innate immune cell recruitment to the lung tissue during bacteremic pneumonia.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26829988      PMCID: PMC4761482          DOI: 10.4049/jimmunol.1402518

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Trace elements and electrolytes in human resting mixed saliva after exercise.

Authors:  J L Chicharro; V Serrano; R Ureña; A M Gutierrez; A Carvajal; P Fernández-Hernando; A Lucía
Journal:  Br J Sports Med       Date:  1999-06       Impact factor: 13.800

2.  Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children.

Authors:  D Bogaert; A van Belkum; M Sluijter; A Luijendijk; R de Groot; H C Rümke; H A Verbrugh; P W M Hermans
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

3.  Pneumococcal bacteraemia.

Authors:  S H Gillespie; P H McWhinney; C C Kibbler
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

4.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 5.  The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae.

Authors:  J C Paton
Journal:  Trends Microbiol       Date:  1996-03       Impact factor: 17.079

6.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

7.  Coexistence of CD14-dependent and independent pathways for stimulation of human monocytes by gram-positive bacteria.

Authors:  A Cauwels; E Wan; M Leismann; E Tuomanen
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

8.  Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space.

Authors:  Ulrich A Maus; Mrigank Srivastava; James C Paton; Matthias Mack; M Brett Everhart; Timothy S Blackwell; John W Christman; Detlef Schlöndorff; Werner Seeger; Jürgen Lohmeyer
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

9.  Molecular characterization of PcpA: a novel choline-binding protein of Streptococcus pneumoniae.

Authors:  A R Sánchez-Beato; R López; J L García
Journal:  FEMS Microbiol Lett       Date:  1998-07-01       Impact factor: 2.742

10.  Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia.

Authors:  J B Rubins; D Charboneau; C Fasching; A M Berry; J C Paton; J E Alexander; P W Andrew; T J Mitchell; E N Janoff
Journal:  Am J Respir Crit Care Med       Date:  1996-04       Impact factor: 21.405

View more
  5 in total

1.  Comparison of specific in-vitro virulence gene expression and innate host response in locally invasive vs colonizer strains of Streptococcus pneumoniae.

Authors:  Naoko Fuji; Michael E Pichichero; Ravinder Kaur
Journal:  Med Microbiol Immunol       Date:  2021-03-22       Impact factor: 3.402

2.  Streptococcus pneumoniae in the heart subvert the host response through biofilm-mediated resident macrophage killing.

Authors:  Anukul T Shenoy; Terry Brissac; Ryan P Gilley; Nikhil Kumar; Yong Wang; Norberto Gonzalez-Juarbe; Whitney S Hinkle; Sean C Daugherty; Amol C Shetty; Sandra Ott; Luke J Tallon; Jessy Deshane; Hervé Tettelin; Carlos J Orihuela
Journal:  PLoS Pathog       Date:  2017-08-25       Impact factor: 6.823

Review 3.  Competitive Cell Death Interactions in Pulmonary Infection: Host Modulation Versus Pathogen Manipulation.

Authors:  Ethan S FitzGerald; Nivea F Luz; Amanda M Jamieson
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

4.  Streptococcus pneumoniae binds to host GAPDH on dying lung epithelial cells worsening secondary infection following influenza.

Authors:  Sang-Sang Park; Norberto Gonzalez-Juarbe; Ashleigh N Riegler; Hansol Im; Yvette Hale; Maryann P Platt; Christina Croney; David E Briles; Carlos J Orihuela
Journal:  Cell Rep       Date:  2021-06-15       Impact factor: 9.423

Review 5.  Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines.

Authors:  Ninecia R Scott; Beth Mann; Elaine I Tuomanen; Carlos J Orihuela
Journal:  Vaccines (Basel)       Date:  2021-03-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.